BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib’s potential to improve efficacy of checkpoint inhibitors presented at AACR
Bergen, Norway, 18 April 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that promising preclinical data with its lead AXL inhibitor bemcentinib (formerly BGB324) has been presented in a poster at the 2018 American Association for Cancer Research (AACR) Annual Meeting on 14-18 April in Chicago, IL, USA.The data highlight bemcentinib’s potential to reverse tumour immune suppression and enhance immune checkpoint inhibitor efficacy. The authors show that bemcentinib